microdosing glp-1 for menopause Weight Gain During Menopause: Solutions in the Era of GLP1-agonists Microdosing GLP-1 in Perimenopause &

This clinic gives members access to a multidisciplinary care team and access to and management of these medications

SEMA, as a treatment for obesity, has shown nephroprotective effects, with a 22% reduction in the composite renal endpoint in the SELECT33 trial in patients without diabetes, supporting the role of SEMA in the management of the cardio-renal-metabolic syndrome

Their primary mechanisms include enhancing insulin secretion in response to glucose, suppressing glucagon release, and slowing gastric emptying

For sensitive patients: Take half a tablet every other day in the morning, working up to a whole tablet every other day